The effect of a probiotic compound in dyspeptic patients [Eficácia terapêutica de composto probiótico em pacientes dispépticos]

Therapeutic efficacy of a probiotic compaond in dyspeptic patients: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN22923997

Enrollment

150

Registered

2012-01-31

Start date

2012-01-15

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyespesia Digestive System Dyspepsia

Interventions

150 patients with functional dyspepsia will be divided into three groups: 1. Probiotic 2. Probiotic + lipid 3. Placebo They will receive the products for 3 months, symptoms and biochemistry will be a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Must have diagnosis of functional dyspepsia (Rome III criteria) 2. Signed informed consent 3. Aged between 18 and 80

Exclusion criteria

Exclusion criteria: 1. Abdominal surgery 2. Major commorbidities that lead to use of drugs which can interfere with symptoms or modify gastric or bowel motility 3. Gastroesophageal reflux disease (GERD) 4. Active peptic ulcer disease (PUD) 5. Use of non steroidal anti inflammatory drugs (NSAIDs) or antibiotics 6. Gastrointestinal (GI) tract neoplasia 7. Pregnant women 8. History of yogurt intolerance or allergy

Design outcomes

Primary

Measure	Time frame
1. The Short-Form Leeds Dyspepsia Questionnaire 2. Biochemistry of ghrelin and leptin levels	—

Secondary

Measure	Time frame
1. Adverse events 2. Compliance 3. Bowel habit 4. Body Mass Index (BMI)	—

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026